Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
China Pharma Holdings Inc (CPHI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/10/2025: CPHI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -83.56% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 5.96M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 0.75 | 52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 |
52 Weeks Range 1.20 - 3.35 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -106.3% | Operating Margin (TTM) -66.76% |
Management Effectiveness
Return on Assets (TTM) -18.22% | Return on Equity (TTM) -59.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 9050107 | Price to Sales(TTM) 1.39 |
Enterprise Value 9050107 | Price to Sales(TTM) 1.39 | ||
Enterprise Value to Revenue 2.11 | Enterprise Value to EBITDA -225.89 | Shares Outstanding 3262000 | Shares Floating 2640623 |
Shares Outstanding 3262000 | Shares Floating 2640623 | ||
Percent Insiders 30.26 | Percent Institutions 1.04 |
Upturn AI SWOT
China Pharma Holdings Inc
Company Overview
History and Background
China Pharma Holdings Inc. was founded in 2001 and is a pharmaceutical company based in China. It has focused on the research, development, manufacturing, and marketing of pharmaceutical products. Key milestones have included product approvals and expansions into new therapeutic areas. The company has evolved by adapting to the changing regulatory landscape and market demands in China's growing healthcare sector.
Core Business Areas
- Active Pharmaceutical Ingredients (APIs): Production and sale of active pharmaceutical ingredients used in the manufacturing of finished drug products.
- Finished Pharmaceutical Products: Development, manufacturing, and marketing of a range of finished pharmaceutical products across various therapeutic categories.
- Research and Development: Investment in R&D to discover and develop new drugs and improve existing formulations.
Leadership and Structure
The leadership team and organizational structure details for China Pharma Holdings Inc. are not readily available in a consolidated public format. Typically, such companies would have a CEO, CFO, and heads of various departments like R&D, manufacturing, sales, and marketing.
Top Products and Market Share
Key Offerings
- Product Name 1: Specific product details, market share data, revenue contributions, and competitor information for China Pharma Holdings Inc.'s key offerings are not publicly disclosed in a granular manner. As a company operating primarily within China, its products would compete with both domestic and international pharmaceutical companies in their respective therapeutic areas.
Market Dynamics
Industry Overview
The pharmaceutical industry in China is characterized by rapid growth driven by an aging population, increasing disposable incomes, and government initiatives to improve healthcare access. The market is highly competitive, with a growing emphasis on innovation, generics, and biopharmaceuticals. Regulatory changes and price controls also play a significant role.
Positioning
China Pharma Holdings Inc. operates within the Chinese pharmaceutical market. Its positioning is likely as a domestic player focusing on both APIs and finished formulations, aiming to capture a share of the growing demand for affordable and effective medicines. Its competitive advantages would stem from its understanding of the local market, existing distribution networks, and manufacturing capabilities.
Total Addressable Market (TAM)
The total addressable market for pharmaceuticals in China is substantial and continues to grow, estimated to be in the hundreds of billions of US dollars annually. China Pharma Holdings Inc. would be seeking to capture a segment of this market, with its positioning dependent on its product portfolio and market penetration within specific therapeutic areas.
Upturn SWOT Analysis
Strengths
- Established presence in the Chinese pharmaceutical market.
- Manufacturing capabilities for APIs and finished products.
- Potential for leveraging domestic market understanding.
Weaknesses
- Limited public information on specific product performance and market share.
- Potential reliance on domestic market, limiting global reach.
- Intense competition within the Chinese pharmaceutical sector.
Opportunities
- Growing demand for pharmaceuticals in China due to an aging population and increased healthcare spending.
- Government support for the domestic pharmaceutical industry.
- Expansion into new therapeutic areas or product categories through R&D or partnerships.
Threats
- Intensifying competition from domestic and international pharmaceutical companies.
- Government price control policies impacting profitability.
- Regulatory changes and compliance challenges.
- Economic downturns affecting consumer spending on healthcare.
Competitors and Market Share
Key Competitors
- Specific key competitors for China Pharma Holdings Inc. are not definitively listed with market share percentages in public domain summaries. Operating in China, its competitors would include major domestic pharmaceutical giants and international companies with a presence in China.
- Sinopharm
- Shanghai Pharmaceuticals Holding
- Jiangsu Hengrui Medicine
Competitive Landscape
China Pharma Holdings Inc. faces a highly competitive landscape within China. Its advantages may lie in its established domestic operations and understanding of local regulations. Disadvantages could include smaller scale compared to national giants and potentially less R&D investment in cutting-edge therapeutics.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends for China Pharma Holdings Inc. are not clearly documented in publicly accessible, structured data. The company's growth would be influenced by its product pipeline, market penetration, and overall market conditions in China.
Future Projections: Specific analyst projections for China Pharma Holdings Inc.'s future growth are not widely published. Any projections would be speculative and depend on company-specific developments and market trends.
Recent Initiatives: Information on recent strategic initiatives undertaken by China Pharma Holdings Inc. is not consistently or readily available in public domain summaries.
Summary
China Pharma Holdings Inc. operates within the dynamic and growing Chinese pharmaceutical market. While it has manufacturing capabilities and a domestic presence, detailed financial and strategic information is not readily available, making a comprehensive assessment difficult. The company faces intense competition and regulatory challenges, but also benefits from China's increasing healthcare demand. Its future success will depend on its ability to innovate, expand its product portfolio, and navigate the evolving market landscape.
Similar Stocks
Sources and Disclaimers
Data Sources:
- General industry reports on the Chinese pharmaceutical market.
- Publicly available company information (limited in depth for this specific entity).
Disclaimers:
This analysis is based on publicly available information and general industry knowledge. Specific financial data and strategic details for China Pharma Holdings Inc. are not consistently and comprehensively disclosed, which may affect the accuracy and completeness of the assessment. This information should not be considered financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About China Pharma Holdings Inc
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2002-04-17 | President, CEO, Chairman & Interim CFO Ms. Zhilin Li | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 224 | |
Full time employees 224 | |||
China Pharma Holdings, Inc. develops, manufactures, and markets pharmaceutical products for human use in the People's Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection for edema diseases, hypertension, acute renal failure, hyperkalemia, hypercalcemia, and acute drug poisoning; and Candesartan for hypertension. It offers Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and Pseudophedrine Hydrochlorida sustained release tablets. It offers Hepatocyte growth-promoting factors, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Additionally, the company provides Vitamin B6 injection; Granisetron Hydrochloride injection for nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. It supplies its products to hospitals and OTC pharmacies through provincial and municipal pharmaceutical logistics companies. The company is based in Haikou, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.